Literature DB >> 21332888

The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study.

R Klamroth1, H Pollmann, C Hermans, A Faradji, A S Yarlas, J D Epstein, B M Ewenstein.   

Abstract

Studies with haemophilia A (HA) patients have shown burden in health-related quality of life (HRQOL) when compared with general population norms. In the current study, HA patients' SF-36v2 health survey scores were compared with general population norms and to patients with other chronic conditions. The impact of target joints (TJs) on HRQOL was also examined. The sample was a subset of HA patients enrolled in the Post-Authorization Safety Surveillance (PASS) programme: a prospective open-label study in which ADVATE [Antihaemophilic Factor (Recombinant), Plasma/Albumin-Free Method] was prescribed. A total of 205 patients who were ≥ 18 years old and had SF-36v2 baseline scores were selected for this study. To measure the burden of HA on HRQOL, manova analyses compared these SF-36v2 scores to age- and gender-matched general population US and EU norms and to patients from other chronic condition groups. manova and correlational analyses examined the relations among TJ, age and SF-36v2 scores. Comparisons with general population norms confirm that HA negatively impacts physical, but not mental, HRQOL. Comparison with other chronic conditions shows the physical burden of HA is greater than for chronic back pain but similar to diabetes and rheumatoid arthritis, while the mental burden of HA is less than for all three patient groups. The presence of TJs was negatively associated with physical HRQOL, although this association was much larger for older patients (45+ years) than for younger ones. Physical, but not mental, HRQOL is diminished in HA patients. Target joints are associated with lower physical HRQOL, although this effect is moderated by age.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21332888     DOI: 10.1111/j.1365-2516.2010.02435.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  16 in total

1.  Arthroscopic partial anterior synovectomy of the knee on patients with haemophilia.

Authors:  Adriano Marques de Almeida; Marcia Uchoa de Rezende; Felippi Guizardi Cordeiro; Paula Ribeiro Villaça; Elbio Antonio D'Amico; Arnaldo José Hernandez; Gilberto Luis Camanho
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2015-03       Impact factor: 4.342

2.  A preliminary case series evaluating the safety and immediate to short-term clinical benefits of joint mobilization in hemophilic arthritis of the lower limb.

Authors:  Emma Scaddan; John Rowell; Shaun O'Leary
Journal:  J Man Manip Ther       Date:  2016-11-17

3.  The social burden and quality of life of patients with haemophilia in Italy.

Authors:  Yllka Kodra; Marianna Cavazza; Arrigo Schieppati; Marta De Santis; Patrizio Armeni; Romano Arcieri; Gabriele Calizzani; Giovanni Fattore; Lamberto Manzoli; Lorenzo Mantovani; Domenica Taruscio
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

4.  Prophylaxis therapy in paediatric patients with haemophilia: a survey of clinical management trends in Italy.

Authors:  Giancarlo Castaman; Angiola Rocino; M Gabriella Mazzucconi; Ezio Zanon; Fabio Gagliano; Angelo C Molinari
Journal:  Blood Transfus       Date:  2015-05-14       Impact factor: 3.443

5.  Declining trends in invasive orthopedic interventions for people with hemophilia enrolled in the Universal Data Collection program (2000-2010).

Authors:  P Tobase; H Lane; A-E-A Siddiqi; R Ingram-Rich; R S Ward
Journal:  Haemophilia       Date:  2016-03-31       Impact factor: 4.287

Review 6.  Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

7.  Social/economic costs and quality of life in patients with haemophilia in Europe.

Authors:  Marianna Cavazza; Yllka Kodra; Patrizio Armeni; Marta De Santis; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; László Gulácsi; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-05

8.  The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease.

Authors:  Séverine Henrard; Brecht Devleesschauwer; Philippe Beutels; Michael Callens; Frank De Smet; Cedric Hermans; Niko Speybroeck
Journal:  Orphanet J Rare Dis       Date:  2014-03-21       Impact factor: 4.123

9.  Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A.

Authors:  Terry Mizrahi; Jean St-Louis; Nancy L Young; Francine Ménard; Nichan Zourikian; Evemie Dubé; Georges E Rivard
Journal:  BMC Hematol       Date:  2016-11-08

Review 10.  Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.

Authors:  Erik Berntorp; Gerald Spotts; Lisa Patrone; Bruce M Ewenstein
Journal:  Biologics       Date:  2014-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.